Literature DB >> 8341644

Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro.

M C Hsu1, U Dhingra, J V Earley, M Holly, D Keith, C M Nalin, A R Richou, A D Schutt, S Y Tam, M J Potash.   

Abstract

The transactivator of transcription, Tat, of human immunodeficiency virus type 1 (HIV-1) is required for viral replication. Inhibition of Tat function could have the potential to keep integrated provirus in dormancy. In the presence of Tat, Ro 24-7429, an analog of Ro 5-3335, inhibited expression of indicator genes controlled by the HIV-1 long terminal repeat promoter in transient transfection assays and in a constitutive cell line at noncytotoxic concentrations. Reduction of steady-state mRNA of the indicator gene by the compound correlated with reduction of the gene product in the constitutive cell line. Ro 24-7429 has broad activity against several strains of HIV-1 in different cell lines, peripheral blood lymphocytes, and macrophages (IC90 = 1-3 microM). Importantly, Ro 24-7429 inhibited viral replication in both acute and chronic infection in vitro, a characteristic expected of a Tat antagonist and not shared by viral reverse transcriptase inhibitors. Consistent with this, the compound reduced cell-associated viral RNA and proteins and partially restored cell-surface CD4 in chronically infected cells. After 2 years of continued weekly passage of the virus in fresh CEM cells grown in the presence of the compound at 1 or 10 microM, the virus did not develop resistance to the drug. These results indicate that the compound's action might involve a cellular factor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341644      PMCID: PMC46938          DOI: 10.1073/pnas.90.14.6395

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  New human gene encoding a positive modulator of HIV Tat-mediated transactivation.

Authors:  H Shibuya; K Irie; J Ninomiya-Tsuji; M Goebl; T Taniguchi; K Matsumoto
Journal:  Nature       Date:  1992-06-25       Impact factor: 49.962

2.  Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

Authors:  C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors.

Authors:  H Kato; H Sumimoto; P Pognonec; C H Chen; C A Rosen; R G Roeder
Journal:  Genes Dev       Date:  1992-04       Impact factor: 11.361

4.  Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication.

Authors:  M Kessler; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

6.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

Authors:  J H Nunberg; W A Schleif; E J Boots; J A O'Brien; J C Quintero; J M Hoffman; E A Emini; M E Goldman
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A.

Authors:  W M Flanagan; B Corthésy; R J Bram; G R Crabtree
Journal:  Nature       Date:  1991-08-29       Impact factor: 49.962

8.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

9.  Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist.

Authors:  M C Hsu; A D Schutt; M Holly; L W Slice; M I Sherman; D D Richman; M J Potash; D J Volsky
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

10.  A human T-cell line resistant to cytopathic effects of the human immunodeficiency virus (HIV).

Authors:  D Casareale; M Stevenson; K Sakai; D J Volsky
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

View more
  24 in total

1.  Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Authors:  Kylene Kehn-Hall; Irene Guendel; Lawrence Carpio; Leandros Skaltsounis; Laurent Meijer; Lena Al-Harthi; Joseph P Steiner; Avindra Nath; Olaf Kutsch; Fatah Kashanchi
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

2.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 3.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 4.  Fate-Regulating Circuits in Viruses: From Discovery to New Therapy Targets.

Authors:  Anand Pai; Leor S Weinberger
Journal:  Annu Rev Virol       Date:  2017-08-11       Impact factor: 10.431

5.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives.

Authors:  M Baba; M Okamoto; M Makino; Y Kimura; T Ikeuchi; T Sakaguchi; T Okamoto
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species.

Authors:  M Baba; M Okamoto; H Takeuchi
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences.

Authors:  M Braddock; P Cannon; M Muckenthaler; A J Kingsman; S M Kingsman
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

9.  Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription.

Authors:  Olaf Kutsch; David N Levy; Paula J Bates; Julie Decker; Barry R Kosloff; George M Shaw; W Priebe; Etty N Benveniste
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  CT-2576, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virus.

Authors:  D W Leung; P K Peterson; R Weeks; G Gekker; C C Chao; A H Kaplan; N Balantac; C Tompkins; G E Underiner; S Bursten
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.